Hainan Huluwa Pharmaceutical Group (605199.SH): Injection Lansoprazole passes generic drug consistency evaluation.

Hainan Huluwa Pharmaceutical Group (605199.SH) announced that it has recently received the Approval Notice for the Supplementary Application of Injection Lansoprazole issued by the National Medical Products Administration. The drug has passed the evaluation of generic drug quality and efficacy consistency. Injection Lansoprazole is used for bleeding gastric, duodenal ulcers, acute stress ulcers, and acute gastric mucosal damage when oral therapy is not applicable. As of the announcement date, apart from the company, 27 other companies have passed the consistency evaluation for this drug. The company has invested a total of RMB 7.5819 million (unaudited) in the research and development of this drug for consistency evaluation.